Business Context and Reporting Period
This Form 8-K is filed by TScan Therapeutics, Inc. (TCRX) on August 12, 2026. The report discloses the termination of a Material Definitive Agreement with Amgen Inc. regarding a Research Collaboration and License Agreement originally dated May 8, 2023.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. It references historical financial terms of the terminated agreement:
- Upfront Payment: $30.0 million (received in 2023).
- Success-Based Milestones: Over $500 million in aggregate (potential).
- Royalties: Tiered single-digit percentages on net sales.
- Termination Penalty: None payable by the Company.
Material Changes
Amgen exercised its right to terminate the Collaboration Agreement in its entirety with 90 days' prior written notice. The termination will become effective on November 10, 2026. Consequently, the Company is obligated to wind down activities under the current research plan, and licenses granted to Amgen will terminate upon the effective date.
Outlook, Risks, and Management Commentary
Following the effective date of termination, the Company does not expect to receive future milestone or royalty payments unless Amgen, its affiliates, or sublicensees continue to exploit product candidates developed during the collaboration. If exploitation continues, applicable milestone and royalty obligations will survive. The primary risk is the loss of potential future revenue streams exceeding $500 million in milestones and ongoing royalties.
Investor Verification Checklist
- Confirm the exact effective date of termination (November 10, 2026) and the status of the wind-down process.
- Verify if any product candidates were advanced to a stage where milestone payments were already triggered prior to termination.
- Assess the impact of the lost collaboration on the Company's cash runway and future funding requirements.
- Review the full text of the Collaboration Agreement (Exhibit 10.1 to the June 30, 2023, 10-Q) for specific survival clauses regarding intellectual property.